| Popis: |
Jiahuan Huang,1,2 Lei Lei,1,2 Bo Chen,2,3 Guoqiang Pan,4 Xiaojiao Wang,1,2 Meiyu Fang2,5 1Department of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, 310022, People’s Republic of China; 2Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, 310022, People’s Republic of China; 3Department of Pathology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, 310022, People’s Republic of China; 4Department of Thoracic Oncology, Wenzhou Medical University, Wenzhou, 325035, People’s Republic of China; 5Department of Medical Oncology of Rare Cancer and Head and Neck Cancer, Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Key Laboratory of Head and Neck Cancer Translational Research of Zhejiang Province, Hangzhou, Zhejiang, 310022, People’s Republic of ChinaCorrespondence: Meiyu Fang Department of Medical Oncology of Rare Cancer and Head and Neck CancerCancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Key Laboratory of Head and Neck Cancer Translational Research of Zhejiang Province, Hangzhou, 310022, People’s Republic of ChinaTel +86-571-88122222Email fangmy@zjcc.org.cnXiaojiao WangDepartment of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, 310022, People’s Republic of ChinaTel +86-571-88122222Email wxiaojia0803@163.comBackground: Sarcomatoid carcinoma (SaCa) of the palatine tonsil is a rare and aggressive subset of head and neck (H&N) cancer which is characterized by insensitivity to surgery and radiotherapy and a poor prognosis. Immunotherapy has led advances in the treatment of melanoma and H&N cancer, but the combined effects of immunotherapy and chemotherapy have not been sufficiently investigated.Case Presentation: Herein, we report the case of 29-year-old Chinese women with local advanced non-resectable SaCa of the palatine tonsil who exhibited a substantial partial response to toripalimab and chemotherapy followed by radiation therapy. To the best of our knowledge, this is the first report of its successful application in this context.Conclusion: Toripalimab combined with chemotherapy may be an effective approach for locally advanced H&N cancer in rare categories of patients, which was the first application as far as we know.Keywords: chemotherapy, combination therapy, palatine tonsil cancer, PD-1 inhibitor, sarcomatoid carcinoma |
